Klinične študije za Debelost v New Jersey
20 študij za Debelost išče udeležence na lokacijah v New Jersey.
Mesta v New Jersey
Uradno besedilo študije (angleško)
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Somerset
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Hackensack University Medical Center, Hackensack
Vključevanje udeležencevFaza 3
Starost 6–17 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Hypertension & Nephrology Association, Eatontown
- IMA Clinical Research Warren, Warren Township
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Eatontown
- Research Site, Somerset
- Research Site, Warren Township
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- CardioMetabolic Collaborative Clinic, Somerset
Vključevanje udeležencevFaza 3
Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- IMA Clinical Research Warren, Warren Township
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07321886A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Jersey City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Virtua Health Incorporated, Marlton
- Saint Michaels Medical Center, Newark
- CardioMetabolic Collaborative Clinic, Somerset
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07037459A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Clinical Research of Philadelphia, Pennington
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06897475A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Premier Research, Trenton
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Psoriasis Treatment Center of Central New Jersey, East Windsor
- Care Access - Hoboken, Hoboken
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Premier Research, Trenton
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Jersey City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Heart House - Vineland, Elmer
- Advanced Cardiology LLC - Hackettstown, Hackettstown
- The Heart House Haddon Heights, Haddon Heights
- in še 5
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07567001Metabolic Health, Bones and Nuts During Weight Loss in Adults
- Rutgers University - NJ Inst Food Nutrition & Health, New Brunswick
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 50–75 · Vsi spoli · Posodobljeno 13. maj 2026 · NCT06949280A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Vanda Investigational Site, Hamilton
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
Starost 18–65 · Vsi spoli · Posodobljeno 20. apr. 2026 · NCT07446439A Study of a Weight Loss Intervention in People With Endometrial Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
Vključevanje udeležencevZgodnja faza 1
Starost 18 in več · Ženske · Posodobljeno 13. apr. 2026 · NCT06751589A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
- Frontage Clinical Services, Inc., Secaucus
Vključevanje udeležencevFaza 1
Starost 18–65 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07465965Extracellular Vesicles, Insulin Action, and Exercise
- Institute for Food, Nutrition, and Health, New Brunswick
- Robert Wood Johnson University Hospital Clinical Research Center, New Brunswick
- Rutgers University Loree Gymnasium, New Brunswick
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 30–80 · Vsi spoli · Posodobljeno 23. jan. 2026 · NCT06546085IVIG vs SCIG in CIDP
- Rutgers, The State University of New Jersey Clinical Research Center, New Brunswick
Vključevanje udeležencevFaza 1
Starost 18–65 · Vsi spoli · Posodobljeno 11. dec. 2025 · NCT05584631Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.